BAX vs. PODD, TFX, RMD, GMED, DXCM, BDX, WST, SWAV, SOLV, and PEN
Should you be buying Baxter International stock or one of its competitors? The main competitors of Baxter International include Insulet (PODD), Teleflex (TFX), ResMed (RMD), Globus Medical (GMED), DexCom (DXCM), Becton, Dickinson and Company (BDX), West Pharmaceutical Services (WST), Shockwave Medical (SWAV), Solventum (SOLV), and Penumbra (PEN). These companies are all part of the "surgical & medical instruments" industry.
Baxter International (NYSE:BAX) and Insulet (NASDAQ:PODD) are both large-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, earnings, community ranking, media sentiment, profitability, dividends, valuation, analyst recommendations and institutional ownership.
Baxter International currently has a consensus target price of $46.30, indicating a potential upside of 14.69%. Insulet has a consensus target price of $243.21, indicating a potential upside of 41.45%. Given Insulet's stronger consensus rating and higher probable upside, analysts plainly believe Insulet is more favorable than Baxter International.
Baxter International has a net margin of 17.77% compared to Insulet's net margin of 12.16%. Insulet's return on equity of 32.19% beat Baxter International's return on equity.
In the previous week, Baxter International had 12 more articles in the media than Insulet. MarketBeat recorded 18 mentions for Baxter International and 6 mentions for Insulet. Insulet's average media sentiment score of 1.35 beat Baxter International's score of 0.45 indicating that Insulet is being referred to more favorably in the news media.
Baxter International received 20 more outperform votes than Insulet when rated by MarketBeat users. Likewise, 66.30% of users gave Baxter International an outperform vote while only 65.98% of users gave Insulet an outperform vote.
90.2% of Baxter International shares are held by institutional investors. 0.2% of Baxter International shares are held by insiders. Comparatively, 0.5% of Insulet shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Baxter International has higher revenue and earnings than Insulet. Baxter International is trading at a lower price-to-earnings ratio than Insulet, indicating that it is currently the more affordable of the two stocks.
Baxter International has a beta of 0.62, meaning that its share price is 38% less volatile than the S&P 500. Comparatively, Insulet has a beta of 0.98, meaning that its share price is 2% less volatile than the S&P 500.
Summary
Insulet beats Baxter International on 10 of the 18 factors compared between the two stocks.
Get Baxter International News Delivered to You Automatically
Sign up to receive the latest news and ratings for BAX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BAX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Baxter International Competitors List
Related Companies and Tools
